Golimumab monotherapy in Japanese patients with active rheumatoid arthritis despite prior treatment with disease-modifying antirheumatic drugs: results of the phase 2/3, multicentre, randomised, double-blind, placebo-controlled GO-MONO study through 24 weeks

Samankaltaisia teoksia

• Golimumab in combination with methotrexate in Japanese patients with active rheumatoid arthritis: results of the GO-FORTH study
  Tekijä: Tanaka, Yoshiya, et al.
  Julkaistu: (2011)
• Clinical efficacy, radiographic progression, and safety through 156 weeks of therapy with subcutaneous golimumab in combination with methotrexate in Japanese patients with active rheumatoid arthritis despite prior methotrexate therapy: final results of the randomized GO-FORTH trial
  Tekijä: Tanaka, Yoshiya, et al.
  Julkaistu: (2016)
• Effect of Methotrexate Plus Adalimumab on the Achievement of Rheumatoid Arthritis Therapeutic Goals: Post Hoc Analysis of Japanese Patients (MELODY Study)
  Tekijä: Koike, Takao, et al.
  Julkaistu: (2015)
• Long-term efficacy and safety of certolizumab pegol in Japanese rheumatoid arthritis patients with an inadequate response to methotrexate: 52-week results from an open-label extension of the J-RAPID study
  Tekijä: Tanaka, Yoshiya, et al.
  Julkaistu: (2014)
• Adalimumab discontinuation in patients with early rheumatoid arthritis who were initially treated with methotrexate alone or in combination with adalimumab: 1 year outcomes of the HOPEFUL-2 study
  Tekijä: Tanaka, Yoshiya, et al.
  Julkaistu: (2016)